Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission tomography and pre- and on-treatment flowcytometric T-cell p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204745 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035415245914112 |
|---|---|
| author | Frank J. Borm Jasper Smit Joyce Bakker Maurits Wondergem Egbert F. Smit Adrianus J. de Langen Tanja D. de Gruijl |
| author_facet | Frank J. Borm Jasper Smit Joyce Bakker Maurits Wondergem Egbert F. Smit Adrianus J. de Langen Tanja D. de Gruijl |
| author_sort | Frank J. Borm |
| collection | DOAJ |
| description | Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission tomography and pre- and on-treatment flowcytometric T-cell profiling in peripheral blood and tumor-draining lymph nodes (TDLN). The on-treatment evaluation was performed 7–14 days after the start of PD-1 blockade in NSCLC patients. These data were related to (pathological) tumor response, progression-free survival, and overall survival (OS). We found that increases in total lesion glycolysis (TLG) had a strong reverse correlation with OS (r = −0.93, p = 0.022). Additionally, responders showed decreased and progressors increased Treg frequencies on-treatment. Frequencies of detectable PD-1-expressing CD8+ T cells decreased in responders but remained stable in progressors. This was especially found in the TDLN. Changes in activated Treg rates in TDLN were strongly but, due to low numbers of data points, non-significantly correlated with ΔTLG and reversely correlated with OS. |
| format | Article |
| id | doaj-art-b3bac891f09a4fdfb2e410416d7ae4df |
| institution | DOAJ |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-b3bac891f09a4fdfb2e410416d7ae4df2025-08-20T02:57:29ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2204745Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodesFrank J. Borm0Jasper Smit1Joyce Bakker2Maurits Wondergem3Egbert F. Smit4Adrianus J. de Langen5Tanja D. de Gruijl6Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The NetherlandsDepartment of Thoracic Oncology, NKI-AvL, Amsterdam, The NetherlandsAmsterdam UMC Location Vrije Universiteit, Medical Oncology, Amsterdam, NetherlandsDepartment of Nuclear Medicine, NKI-AvL, Amsterdam, The NetherlandsDepartment of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The NetherlandsDepartment of Thoracic Oncology, NKI-AvL, Amsterdam, The NetherlandsAmsterdam UMC Location Vrije Universiteit, Medical Oncology, Amsterdam, NetherlandsBetter biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive value of early response evaluation using Fluor-18-deoxyglucose positron emission tomography and pre- and on-treatment flowcytometric T-cell profiling in peripheral blood and tumor-draining lymph nodes (TDLN). The on-treatment evaluation was performed 7–14 days after the start of PD-1 blockade in NSCLC patients. These data were related to (pathological) tumor response, progression-free survival, and overall survival (OS). We found that increases in total lesion glycolysis (TLG) had a strong reverse correlation with OS (r = −0.93, p = 0.022). Additionally, responders showed decreased and progressors increased Treg frequencies on-treatment. Frequencies of detectable PD-1-expressing CD8+ T cells decreased in responders but remained stable in progressors. This was especially found in the TDLN. Changes in activated Treg rates in TDLN were strongly but, due to low numbers of data points, non-significantly correlated with ΔTLG and reversely correlated with OS.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204745NSCLCimmunotherapybiomarkerPET–CTTDLNPD-1 inhibitor |
| spellingShingle | Frank J. Borm Jasper Smit Joyce Bakker Maurits Wondergem Egbert F. Smit Adrianus J. de Langen Tanja D. de Gruijl Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes OncoImmunology NSCLC immunotherapy biomarker PET–CT TDLN PD-1 inhibitor |
| title | Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes |
| title_full | Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes |
| title_fullStr | Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes |
| title_full_unstemmed | Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes |
| title_short | Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes |
| title_sort | early response evaluation of pd 1 blockade in nsclc patients through fdg pet ct and t cell profiling of tumor draining lymph nodes |
| topic | NSCLC immunotherapy biomarker PET–CT TDLN PD-1 inhibitor |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2204745 |
| work_keys_str_mv | AT frankjborm earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes AT jaspersmit earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes AT joycebakker earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes AT mauritswondergem earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes AT egbertfsmit earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes AT adrianusjdelangen earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes AT tanjaddegruijl earlyresponseevaluationofpd1blockadeinnsclcpatientsthroughfdgpetctandtcellprofilingoftumordraininglymphnodes |